Specify Company / Ticker to Get the Summary
Adicet Bio Inc
ACETAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts. Address: 131 Dartmouth Street, Boston, MA, United States, 02116
Analytics
WallStreet Target Price
6.4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ACET
Dividend Analytics ACET
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACET
Stock Valuation ACET
Financials ACET
Results | 2019 | Dynamics |